Literature DB >> 3101478

Cigarette smoking-induced coronary vasoconstriction in atherosclerotic coronary artery disease and prevention by calcium antagonists and nitroglycerin.

M D Winniford, D E Jansen, G A Reynolds, P Apprill, W H Black, L D Hillis.   

Abstract

In patients with coronary artery disease, cigarette smoking increases myocardial oxygen demand but may cause an inappropriate alpha-adrenergically mediated fall in myocardial oxygen supply. This study was performed to determine if smoking-induced coronary vasoconstriction is prevented by nitroglycerin, verapamil or nifedipine treatment. In 25 smokers with coronary artery disease (20 men, 5 women, aged 32 to 65 years), heart rate-systolic arterial pressure double product and coronary sinus blood flow (thermodilution) were measured before and during smoking both before and 30 to 60 minutes after administration of saline solution (n = 5, control subjects); nifedipine, 10 mg sublingually (n = 6); verapamil, 10 mg intravenously (n = 7); or nitroglycerin, 0.4 mg sublingually (n = 7). During the first smoking period, double product increased, but coronary sinus flow did not change or decreased. During the second smoking period, in the control subjects double product and coronary sinus flow responded in a manner similar to that observed previously. In those given nifedipine, double product did not change, but coronary sinus flow increased (-4 +/- 5% during the first smoking period [before nifedipine] and 17 +/- 12% during the second period [after nifedipine], p less than 0.01). In those given verapamil, double product and coronary sinus flow increased during smoking (-12 +/- 8% during the first smoking period [before verapamil], 10 +/- 9% during the second period [after verapamil], p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101478     DOI: 10.1016/0002-9149(87)90785-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Effects of transdermal nicotine patches on ambulatory ECG monitoring findings: a double-blind study in healthy smokers.

Authors:  Z Khoury; P Comans; A Keren; T Lerer; A Gavish; D Tzivoni
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

Review 2.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 3.  The benefits of stopping smoking and the role of nicotine replacement therapy in older patients.

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 4.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

5.  Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smoking.

Authors:  R Lassila; H W Seyberth; A Haapanen; H Schweer; M Koskenvuo; K E Laustiola
Journal:  BMJ       Date:  1988-10-15

6.  Does Smoking Act as a Friend or Enemy of Blood Pressure? Let Release Pandora's Box.

Authors:  Aurelio Leone
Journal:  Cardiol Res Pract       Date:  2011-01-19       Impact factor: 1.866

7.  Idiopathic and secondary osteonecrosis of the femoral head show different thrombophilic changes and normal or higher levels of platelet growth factors.

Authors:  Elisabetta Cenni; Caterina Fotia; Enis Rustemi; Kimitachi Yuasa; Giuseppe Caltavuturo; Armando Giunti; Nicola Baldini
Journal:  Acta Orthop       Date:  2011-02-01       Impact factor: 3.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.